(Q45341300)

13 December 2017

title

Prevention of cancer recurrence after treatment for hepatitis C virus-related hepatocellular carcinoma by interferon therapy (English)

1 reference

13 December 2017

1 reference

Shoji Kubo

1

1 reference

13 December 2017

publication date

8 April 2009

1 reference

Clinical journal of gastroenterology

13 December 2017

published in

1 reference

13 December 2017

volume

2

1 reference

13 December 2017

issue

2

1 reference

13 December 2017

page(s)

65-70

1 reference

Viruses and hepatocellular carcinoma

13 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Effects of continuous hepatitis with persistent hepatitis C viremia on outcome after resection of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Prognostic effects of causative virus in hepatocellular carcinoma according to the Japan integrated staging (JIS) score

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Significant influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy. Result of multivariate analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Clinicopathological criteria for multicentricity of hepatocellular carcinoma and risk factors for such carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Relationship between multicentric occurrence of hepatocellular carcinoma and histology of noncancerous hepatic tissue in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Correlation between low platelet count and multicentricity of hepatocellular carcinoma in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Influence of previous interferon therapy on recurrence after resection of hepatitis c virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

The interferons. Mechanisms of action and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Prognostic factors after recurrence of resected hepatocellular carcinoma associated with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Therapeutic modalities in hepatitis C: challenges and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

Second hepatic resection for recurrent hepatocellular carcinoma in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12328-009-0072-1

A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis

21 January 2018

1 reference

12 December 2020

Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group

1 reference

12 December 2020

Patterns of and risk factors for recurrence after liver resection for well-differentiated hepatocellular carcinoma: a special reference to multicentric carcinogenesis after operation

1 reference

12 December 2020

Resected cases of hepatocellular carcinoma detected after interferon therapy for chronic hepatitis C

1 reference

12 December 2020

Additional hepatocellular carcinomas undetectable before surgery

1 reference

12 December 2020

Surgical results in patients with dual hepatitis B- and C-related hepatocellular carcinoma compared with hepatitis B- or C-related hepatocellular carcinoma

1 reference

12 December 2020

Serum concentration of type IV collagen 7S domain as a marker for increased risk of recurrence after liver resection for hepatocellular carcinoma

1 reference

12 December 2020

Human lymphoblastoid interferon. In vitro and in vivo studies in hepatocellular carcinoma

1 reference

12 December 2020

Outcome of patients with hepatitis C virus-related hepatocellular carcinoma occurring after interferon therapy.

1 reference

12 December 2020

High prevalence of infection with hepatitis B and C viruses in patients with hepatocellular carcinoma in Japan

1 reference

12 December 2020

Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study

1 reference

12 December 2020

Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma

1 reference

12 December 2020

Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients

1 reference

12 December 2020

A comparison of the surgical results in patients with hepatitis B versus hepatitis C-related hepatocellular carcinoma

1 reference

12 December 2020

Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan

1 reference

12 December 2020

Surgical treatment for hepatocellular carcinoma detected after successful interferon therapy

1 reference

12 December 2020

Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma

1 reference

12 December 2020

Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma

1 reference

12 December 2020

Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy

1 reference

12 December 2020

Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma

1 reference

12 December 2020

Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis

1 reference

12 December 2020

10.1007/S12328-009-0072-1

Identifiers

DOI

1 reference

Dimensions Publication ID

13 December 2017

1027129016

0 references

1 reference